AtriCure Inc.  

(Public, NASDAQ:ATRC)   Watch this stock  
Find more results for atricure
+0.77 (3.02%)
Aug 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.70 - 26.42
52 week 13.19 - 28.15
Open 25.56
Vol / Avg. 280,480.00/215,743.00
Mkt cap 727.70M
P/E     -
Div/yield     -
EPS -0.59
Shares 28.54M
Beta 0.67
Inst. own 99%
Oct 28, 2015
Q3 2015 AtriCure Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 18, 2015
AtriCure Inc at Morgan Stanley Healthcare Conference - 10:30AM EDT - Add to calendar
Aug 12, 2015
AtriCure Inc at Canaccord Genuity Growth Conference
Jul 28, 2015
Q2 2015 AtriCure Inc Earnings Call - Webcast
Jul 28, 2015
Q2 2015 AtriCure Inc Earnings Release
Jun 24, 2015
AtriCure Inc at JMP Securities Life Sciences Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -15.01% -15.09%
Operating margin -14.79% -15.23%
EBITD margin - -10.78%
Return on average assets -12.55% -11.99%
Return on average equity -15.25% -15.80%
Employees 320 -
CDP Score - -


6217 Centre Park Dr
WEST CHESTER, OH 45069-3866
United States - Map
+1-513-7554107 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AtriCure, Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company's Isolator Synergy System, which includes its Isolator Synergy clamps, generator and switchbox, is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting, and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies, including its Lumitip dissectors and Endoscopic Technologies, Inc.'s (Estech) line of reusable cardiac surgery instruments.

Officers and directors

Richard M. Johnston Independent Chairman of the Board
Age: 80
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael H. Carrel President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
M. Andrew Wade CPA Chief Financial Officer, Senior Vice President
Age: 40
Bio & Compensation  - Reuters
Douglas J. Seith Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Andrew L. Lux Ph.D. Senior Vice President - R&D, Operations and QA
Age: 63
Bio & Compensation  - Reuters
Patricia J. Kennedy Vice President, General Manager - International
Age: 54
Bio & Compensation  - Reuters
Mark A. Collar Independent Director
Age: 62
Bio & Compensation  - Reuters
Scott William Drake Independent Director
Age: 47
Bio & Compensation  - Reuters
Michael D. Hooven Independent Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elizabeth D. Krell Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters